Aussie PBS Panel Experts Back Coverage Of Pharmaxis CF Drug
This article was originally published in PharmAsia News
Australia’s Pharmaceutical Benefits Scheme experts have recommended coverage of the Pharmaxis cystic fibrosis drug, Bronchitol (mannitol), an inhaled powder still in the second of two Phase III trials.
You may also be interested in...
For the first time, the US FDA granted an emergency use authorization to a device that allows for the home collection of saliva for COVID-19 diagnosis. See what Scott Rabuka, senior director of molecular products at DNA Genotek, which developed the test, said about it here.
Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.